

## THE USE OF ANTIGESTAGENS FOR INHIBITING ACCELERATED ENDOMETRIAL MATURATION DURING INFERTILITY TREATMENT

This application is a continuation in part of U.S. Serial No. 09/756,286 filed January 9, 2001, which is incorporated by reference herein in its entirety.

5

### BACKGROUND OF THE INVENTION

This invention relates to the use of antigestagens for shifting post-ovulatory endometrial maturation during infertility treatment.

Ovarian stimulation with gonadotropins is commonly used in humans in assisted reproductive technologies, including in vitro fertilization and embryo transfer therapy (IVF/ET). However, the post-ovulatory endometrial transformation is advanced after controlled ovarian hyperstimulation (Garcia et al., 1984, *Fertil. Steril.* 41:31-37; Paulson et al., 1997, *Fertil. Steril.* 76:321-325; Kolb, 1997, *Fertil. Steril.* 67:625-630; Franchin et al., 1999, *Fertil. Steril.* 71:174-181.) As a consequence, the usual precisely synchronized temporal development of the endometrium and the embryo is disrupted, resulting in low implantation rates for healthy blastocysts.

10

### SUMMARY OF THE INVENTION

This invention provides a method of enhancing fertility in mammals by the administration of 17 $\alpha$ -fluoralkylated progesterone receptor antagonists to inhibit the advancement of endometrium maturation during infertility (i.e., fertility enhancement) treatment including all assisted reproduction therapies.

It is also contemplated as part of this invention that such a method will be particularly useful in a female mammal undergoing fertility treatment. Fertility treatment, as used herein, refers to any treatment which is rendered to a female mammal for the purposes of achieving a pregnancy, whether or not the mammal has been determined to be fertile, infertile, or to have impaired fertility. Fertility treatments contemplated as part of this invention include, but are not limited to ovarian hyperstimulation (OH), in vitro fertilization and embryo transfer (IVF/ET),

15

and OH in combination with IVF/ET. Particularly, a method of inhibiting advanced endometrial maturation, which typically occurs in conjunction with ovarian hyperstimulation, is contemplated. For example, ovarian hyperstimulation may be used as a tool in fertility treatment in conjunction with, for example, timed intercourse, artificial insemination, intrauterine insemination, IVF/ET, and gamete intra fallopian transfer (GIFT).

IVF/ET, as used herein, refers to any techniques wherein oocytes are fertilized in vitro and then transferred into the female reproductive tract. For example, transfer of the embryo may occur via transfer of the embryo into the uterus through the cervix or via transfer of the embryo into the fallopian tubes (zygote intra fallopian transfer (ZIFT)). Fertilization of oocytes in vitro may be accomplished, for example, by incubating oocytes in the presence of sperm or by intra cytoplasmic sperm injection (ICSI). IVF/ET may also be accomplished using donor eggs. Infertility treatments also include treatments such as induction of ovarian stimulation followed by fertilization by normal coitus.

Ovarian hyperstimulation, as used herein, refers to the use of a follicle stimulating agent to stimulate follicle development. Ovarian hyperstimulation may be used in female subjects having a variety of ovulatory conditions, including subjects who are anovulatory, subjects who have impaired, reduced, or irregular ovulation, and subjects with normal ovulatory patterns. Preferred follicle stimulating agents, include gonadotropins, such as for example, follicle stimulating hormone (FSH), luteinizing hormone (LH), human menopausal gonadotropins (hMG), and human chorionic gonadotropin (hCG). Brand names of gonadotropins that are available for use as follicle stimulating agents, include for example, Perganol, Metrodin, Humegon, Fertinorm, Gonal F, and Primogonyl-1000 etc. Follicle stimulating agents, as used herein, also include estrogen blocking agents such as, for example, clomiphene citrate (commercially available as Clomid and Serophene). Gonadotropins that may be used in accordance with this invention include hormones that are isolated from naturally occurring source materials and hormones that are produced synthetically, including hormones produced through

1000  
999  
998  
997  
996  
995  
994  
993  
992  
991  
990  
989  
988  
987  
986  
985  
984  
983  
982  
981  
980  
979  
978  
977  
976  
975  
974  
973  
972  
971  
970  
969  
968  
967  
966  
965  
964  
963  
962  
961  
960  
959  
958  
957  
956  
955  
954  
953  
952  
951  
950  
949  
948  
947  
946  
945  
944  
943  
942  
941  
940  
939  
938  
937  
936  
935  
934  
933  
932  
931  
930  
929  
928  
927  
926  
925  
924  
923  
922  
921  
920  
919  
918  
917  
916  
915  
914  
913  
912  
911  
910  
909  
908  
907  
906  
905  
904  
903  
902  
901  
900  
899  
898  
897  
896  
895  
894  
893  
892  
891  
890  
889  
888  
887  
886  
885  
884  
883  
882  
881  
880  
879  
878  
877  
876  
875  
874  
873  
872  
871  
870  
869  
868  
867  
866  
865  
864  
863  
862  
861  
860  
859  
858  
857  
856  
855  
854  
853  
852  
851  
850  
849  
848  
847  
846  
845  
844  
843  
842  
841  
840  
839  
838  
837  
836  
835  
834  
833  
832  
831  
830  
829  
828  
827  
826  
825  
824  
823  
822  
821  
820  
819  
818  
817  
816  
815  
814  
813  
812  
811  
810  
809  
808  
807  
806  
805  
804  
803  
802  
801  
800  
799  
798  
797  
796  
795  
794  
793  
792  
791  
790  
789  
788  
787  
786  
785  
784  
783  
782  
781  
780  
779  
778  
777  
776  
775  
774  
773  
772  
771  
770  
769  
768  
767  
766  
765  
764  
763  
762  
761  
760  
759  
758  
757  
756  
755  
754  
753  
752  
751  
750  
749  
748  
747  
746  
745  
744  
743  
742  
741  
740  
739  
738  
737  
736  
735  
734  
733  
732  
731  
730  
729  
728  
727  
726  
725  
724  
723  
722  
721  
720  
719  
718  
717  
716  
715  
714  
713  
712  
711  
710  
709  
708  
707  
706  
705  
704  
703  
702  
701  
700  
699  
698  
697  
696  
695  
694  
693  
692  
691  
690  
689  
688  
687  
686  
685  
684  
683  
682  
681  
680  
679  
678  
677  
676  
675  
674  
673  
672  
671  
670  
669  
668  
667  
666  
665  
664  
663  
662  
661  
660  
659  
658  
657  
656  
655  
654  
653  
652  
651  
650  
649  
648  
647  
646  
645  
644  
643  
642  
641  
640  
639  
638  
637  
636  
635  
634  
633  
632  
631  
630  
629  
628  
627  
626  
625  
624  
623  
622  
621  
620  
619  
618  
617  
616  
615  
614  
613  
612  
611  
610  
609  
608  
607  
606  
605  
604  
603  
602  
601  
600  
599  
598  
597  
596  
595  
594  
593  
592  
591  
590  
589  
588  
587  
586  
585  
584  
583  
582  
581  
580  
579  
578  
577  
576  
575  
574  
573  
572  
571  
570  
569  
568  
567  
566  
565  
564  
563  
562  
561  
560  
559  
558  
557  
556  
555  
554  
553  
552  
551  
550  
549  
548  
547  
546  
545  
544  
543  
542  
541  
540  
539  
538  
537  
536  
535  
534  
533  
532  
531  
530  
529  
528  
527  
526  
525  
524  
523  
522  
521  
520  
519  
518  
517  
516  
515  
514  
513  
512  
511  
510  
509  
508  
507  
506  
505  
504  
503  
502  
501  
500  
499  
498  
497  
496  
495  
494  
493  
492  
491  
490  
489  
488  
487  
486  
485  
484  
483  
482  
481  
480  
479  
478  
477  
476  
475  
474  
473  
472  
471  
470  
469  
468  
467  
466  
465  
464  
463  
462  
461  
460  
459  
458  
457  
456  
455  
454  
453  
452  
451  
450  
449  
448  
447  
446  
445  
444  
443  
442  
441  
440  
439  
438  
437  
436  
435  
434  
433  
432  
431  
430  
429  
428  
427  
426  
425  
424  
423  
422  
421  
420  
419  
418  
417  
416  
415  
414  
413  
412  
411  
410  
409  
408  
407  
406  
405  
404  
403  
402  
401  
400  
399  
398  
397  
396  
395  
394  
393  
392  
391  
390  
389  
388  
387  
386  
385  
384  
383  
382  
381  
380  
379  
378  
377  
376  
375  
374  
373  
372  
371  
370  
369  
368  
367  
366  
365  
364  
363  
362  
361  
360  
359  
358  
357  
356  
355  
354  
353  
352  
351  
350  
349  
348  
347  
346  
345  
344  
343  
342  
341  
340  
339  
338  
337  
336  
335  
334  
333  
332  
331  
330  
329  
328  
327  
326  
325  
324  
323  
322  
321  
320  
319  
318  
317  
316  
315  
314  
313  
312  
311  
310  
309  
308  
307  
306  
305  
304  
303  
302  
301  
300  
299  
298  
297  
296  
295  
294  
293  
292  
291  
290  
289  
288  
287  
286  
285  
284  
283  
282  
281  
280  
279  
278  
277  
276  
275  
274  
273  
272  
271  
270  
269  
268  
267  
266  
265  
264  
263  
262  
261  
260  
259  
258  
257  
256  
255  
254  
253  
252  
251  
250  
249  
248  
247  
246  
245  
244  
243  
242  
241  
240  
239  
238  
237  
236  
235  
234  
233  
232  
231  
230  
229  
228  
227  
226  
225  
224  
223  
222  
221  
220  
219  
218  
217  
216  
215  
214  
213  
212  
211  
210  
209  
208  
207  
206  
205  
204  
203  
202  
201  
200  
199  
198  
197  
196  
195  
194  
193  
192  
191  
190  
189  
188  
187  
186  
185  
184  
183  
182  
181  
180  
179  
178  
177  
176  
175  
174  
173  
172  
171  
170  
169  
168  
167  
166  
165  
164  
163  
162  
161  
160  
159  
158  
157  
156  
155  
154  
153  
152  
151  
150  
149  
148  
147  
146  
145  
144  
143  
142  
141  
140  
139  
138  
137  
136  
135  
134  
133  
132  
131  
130  
129  
128  
127  
126  
125  
124  
123  
122  
121  
120  
119  
118  
117  
116  
115  
114  
113  
112  
111  
110  
109  
108  
107  
106  
105  
104  
103  
102  
101  
100  
99  
98  
97  
96  
95  
94  
93  
92  
91  
90  
89  
88  
87  
86  
85  
84  
83  
82  
81  
80  
79  
78  
77  
76  
75  
74  
73  
72  
71  
70  
69  
68  
67  
66  
65  
64  
63  
62  
61  
60  
59  
58  
57  
56  
55  
54  
53  
52  
51  
50  
49  
48  
47  
46  
45  
44  
43  
42  
41  
40  
39  
38  
37  
36  
35  
34  
33  
32  
31  
30  
29  
28  
27  
26  
25  
24  
23  
22  
21  
20  
19  
18  
17  
16  
15  
14  
13  
12  
11  
10  
9  
8  
7  
6  
5  
4  
3  
2  
1

recombinant DNA techniques. Mutant gonadotropins which retain activity as follicle stimulating agents are also contemplated as part of this invention.

Ovarian hyperstimulation may be accomplished using more than type of follicular stimulating agent. For example, an estrogen blocking agent such as 5 clomiphene may be used in combination with a gonadotropin. Ovarian hyperstimulation may be used to treat a variety of types of infertility, including but not limited to, idiopathic infertility, anovulatory infertility, endometriosis associated infertility, tubal factor infertility and male factor infertility.

Ovarian hyperstimulation may also be accomplished in conjunction with a 10 gonadotropin releasing hormone antagonist (GnRH) to turn off the subjects endogenous hormone production. GnRH's that may be used in conjunction with the invention include, for example, Synarel or Lupron.

In a preferred embodiment, the methods of this invention are employed in conjunction with human female subjects. The methods of this invention may also 15 be employed with other mammalian female subjects, including but not limited to, household pets, farm animals and zoo animals, particularly including cows, pigs, horses, and sheep. When used in fertility treatment of non-human mammals, the administration of antigestagens can help to achieve a higher success rate in, for example, in vitro fertilization and embryo transfer undertaken for economic or breeding purposes.

Non-human mammals which are produced by the methods disclosed herein are also contemplated as part of the invention. These non-human mammals include, 20 for example, mammals which have been genetically modified, including for example, mammals that have been genetically modified using recombinant DNA techniques.

In one aspect, the invention relates to a method of inhibiting the occurrence 25 of advanced endometrium maturation in a human female subject undergoing fertility treatment comprising administering at least one 17 $\alpha$ -fluoralkylated progesterone receptor antagonist to the female subject during the post-ovulatory phase of the endometrial cycle.

In another aspect, the invention relates to a method of achieving pregnancy in a human female subject comprising stimulating the ovaries of the subject by administering a follicle stimulating agent to the subject, wherein the agent comprises follicle stimulating hormone;

5 removing eggs from the ovary of the stimulated subject; administering at least one 17 $\alpha$ -fluoralkylated progesterone receptor antagonist to the subject in the post-ovulatory phase of the endometrial cycle; fertilizing at least one egg in vitro to obtain an embryo; implanting the embryo in the uterus or fallopian tubes of the mammal.

10 In another aspect, the invention relates to a method of inhibiting the occurrence of advanced endometrium maturation in a non-human female mammal undergoing fertility treatment to achieve pregnancy comprising administering at least one 17 $\alpha$ -fluoralkylated progesterone receptor antagonist to the mammal during the post-ovulatory phase of the endometrial cycle.

15 In another aspect, the invention relates to a method of achieving pregnancy in a non-human mammal comprising stimulating the ovaries of the mammal by administering a follicle stimulating agent to the mammal, wherein the agent comprises follicle stimulating hormone; removing eggs from the ovary of the stimulated mammal; administering at least one 17 $\alpha$ -fluoralkylated progesterone receptor antagonist to the mammal in the post-ovulatory phase of the endometrial cycle; fertilizing at least one egg in vitro to obtain an embryo; implanting the embryo in the uterus or fallopian tubes of the mammal.

20 In a further aspect, the invention relates to a method of achieving pregnancy in a female mammal comprising


25 (a) administering gonadotropins for ovarian hyperstimulation to the mammal;  
(b) removing eggs from the ovary of the stimulated animal;  
(c) administering at least one 17 $\alpha$ -fluoralkylated progesterone receptor antagonist;  
(d) fertilizing at least one of the removed eggs in vitro to obtain an embryo  
30 (e) introducing the embryo into the reproductive tract of the mammal.

Preferably, the gonadotropin administered to the mammal to achieve ovarian

hyperstimulation comprises follicle stimulating hormone (FSH). Even more preferably ovarian stimulation is achieved by the use of a first gonadotropin comprising FSH and the subsequent use of second gonadotropin comprising chorionic gonadotropin, particularly human chorionic gonadotropin (hCG).

5 Preferably the embryo is introduced into the reproductive tract of the mammal by introduction into the uterus via the cervix. Also preferably, a gonadotropin releasing hormone (GnRH) agonist or antagonist is administered to the female mammal prior and during the administration of the gonadotropins.

Compounds useful as antigestagens according to the present invention include all 17 $\alpha$ -fluoralkylated progesterone receptor antagonists which possess a strong affinity for the gestagen receptor (progesterone receptor) and show minimal gestagen activity of their own. For example, 17 $\alpha$ -fluoralkylated steroid compounds which may be employed in conjunction with the invention are described U.S. Patent Application Serial No. 09/020,947, WO/98/34947, Wang and Ruan, 1994, *Journal of Fluorine Chemistry* 69:1-3, all of which are hereby incorporated by reference in their entirety. Antigestagens useful for the present invention include but are not limited to, for example, 17 $\alpha$ -fluoroalkyl steroids of general formula I, primarily from the cited disclosures:



I

20 wherein




$R^1$  is methyl or ethyl,

$R^2$  is  $C_nF_mH_o$ , wherein n is 1-6, preferably 2, 3, 4, 5 or 6, m > 1 and  $m+o = 2n+1$ ,

$R^3$  is a free, etherified or esterified hydroxy group,

25  $R^4$  and  $R^5$  each is a hydrogen, or together form an additional bond or a methylene group,

St is a steroidal ABC-ring system of partial formula A, B or C



wherein

5            R<sup>6</sup>        is hydrogen, a straight-chain C<sub>1</sub>-C<sub>4</sub> alkyl group or branched C<sub>3</sub>-C<sub>4</sub> alkyl group or halogen,

10           R<sup>7</sup>        is hydrogen, a straight-chain C<sub>1</sub>-C<sub>4</sub> alkyl group or a branched C<sub>3</sub>-C<sub>4</sub> alkyl group, or

if St is a steroid ABC-ring system A or B, in addition

R<sup>6</sup> and R<sup>7</sup> together can form an additional bond,

X        is oxygen, hydroxyimino (=N-OH) or two hydrogen atoms,

15           R<sup>8</sup>        is Y or aryl that is optionally substituted in several places with a group Y, other than H,

Y        is hydrogen, halogen, -OH, -NO<sub>2</sub>, -N<sub>3</sub>, -CN, -NR<sup>9a</sup>R<sup>9b</sup>, -NHSO<sub>2</sub>R<sup>9</sup>, -CO<sub>2</sub>R<sup>9</sup>, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>1</sub>-C<sub>10</sub> alkanoyloxy, benzoxyloxy, C<sub>1</sub>-C<sub>10</sub> alkanoyl, C<sub>1</sub>-C<sub>10</sub> hydroxyalkyl or benzoyl,

20           R<sup>9a</sup> and R<sup>9b</sup> are the same or different and each is hydrogen or C<sub>1</sub>-C<sub>10</sub> alkyl, R<sup>9</sup> is hydrogen or C<sub>1</sub>-C<sub>10</sub> alkyl,

and for -NR<sup>9a</sup>R<sup>9b</sup> radicals, as well as their physiologically compatible salts with acids and for -CO<sub>2</sub>R<sup>9</sup> radicals with R<sup>9</sup> being hydrogen, as well as their physiologically compatible salts with bases.

25           The wavy lines mean that the substituent in question can be in  $\alpha$ - or  $\beta$ -position.

Suitable alkyl groups within the scope of this formula include methyl, ethyl, or n- or iso-propyl, and n-, iso- or tert-butyl groups.

The other  $C_1$ - $C_{10}$  alkyl groups, Y,  $R^9$ ,  $R^{9a}$ ,  $R^{9b}$ , include the higher homologs in addition, such as, for example, the pentyl, neo-pentyl, and hexyl to decyl groups.

$C_1$ - $C_{10}$  alkyl groups are to be understood to encompass, however, carbocyclic or alkylcycloalkyl groups as well with up to 10 carbon atoms, for example cyclopropyl, cyclopentyl, cycloheptyl, methylcyclopropyl, methylcyclopentyl or methylcyclohexyl. A methyl or ethyl group is preferred for all cases above.

$C_1$ - $C_{10}$  alkoxy groups are the radicals that are lengthened by one oxygen atom and derived from the alkyl groups that are mentioned above, thus, e.g., the methoxy, ethoxy, n- or iso-propoxy, n-, iso- or tert-butoxy radical, etc.

$C_1$ - $C_{10}$  alkanoyl is defined as the acyl radicals of straight-chain and branched  $C_1$ - $C_{10}$  alkanecarboxylic acids, thus, for example, the formyl, acetyl, propionyl, butyryl or iso-butyryl radical, etc.

$C_1$ - $C_{10}$  alkanoyloxy radicals are the radicals of the above alkanoyl radicals that are lengthened by one oxygen atom, thus, e.g., the acetyloxy, propionyloxy, and butyryloxy, etc.

If a halogen atom is mentioned as a substituent, this can be a fluorine, chlorine or bromine atom. Fluorine is preferred.

For radicals  $R^2$ , perfluorinated side chains of length  $n = 2$ -4 are preferred and among the latter, in turn the pentafluoroethyl unit is especially preferred.

$R^3$  stands primarily for a free hydroxy group.

In the case of an etherified or esterified hydroxy group as a  $17\beta$ -substituent, the latter is preferably etherified with a  $C_1$ - $C_{10}$  alkyl group or esterified with a  $C_1$ - $C_{10}$  alkanoyl group. For this alkyl or alkanoyl group, the same meanings as above apply. The etherification or esterification of the hydroxy group is carried out according to the methods that are familiar to one skilled in the art.

$R^4$  and  $R^5$  preferably each are a hydrogen or together form an additional bond.

If  $R^8$  is a group Y, this is preferably a  $C_1$ - $C_{10}$  alkanoyl or (1-hydroxy)- $C_1$ - $C_{10}$  alkyl group; among these, acetyl and propionyl are especially preferred.

Preferred carbocyclic or heterocyclic aryl radicals are phenyl, 1- or 2-naphthalinyl, 2- or 3-furanyl, 2- or 3-benzofuranyl, 2- or 3-thienyl, 2-, 3- or 4-pyridinyl. Substituted aryl radicals  $R^8$ , are primarily 4-cyanophenyl and 4-halophenyl, especially 4-fluorophenyl, can be cited,

5 Among all the radicals that are mentioned as preferred for  $R^8$ ,  $R^8$  in the meaning of Y and Y, in turn, equal to acetyl is especially to be preferred.

The compounds that are mentioned below are especially preferred according to the invention:

10  $11\beta$ -(4-Acetylphenyl)- $17\beta$ -hydroxy- $17\alpha$ -(1,1,2,2,2-pentafluoroethyl)estr-4-en-3-one;

4'-[ $17\beta$ -hydroxy-3-oxo- $17\alpha$ -(1,1,2,2,2-pentafluoroethyl)estr-4-en-11 $\beta$ -yl][1,1'-biphenyl]-4-carbonitrile;

15  $11\beta$ -(4'-fluoro[1,1'-biphenyl]-4-yl)- $17\beta$ -hydroxy- $17\alpha$ -(1,1,2,2,2-pentafluoroethyl)estr-4-en-3-one;

17 $\beta$ -hydroxy- $17\alpha$ -(1,1,2,2,2-pentafluoroethyl)- $11\beta$ -[4-(3-pyridinyl)phenyl]estr-4-en-3-one;

20  $11\beta$ -(4-acetylphenyl)- $17\beta$ -hydroxy- $17\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4,15-dien-3-one;

4'-[ $17\beta$ -hydroxy-3-oxo- $17\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4,15-dien-11 $\beta$ -yl][1,1'-biphenyl]-4-carbonitrile;

25  $11\beta$ -(4'-fluoro[1,1'-biphenyl]-4-yl)- $17\beta$ -hydroxy- $17\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4,15-dien-3-one;

$17\beta$ -hydroxy- $17\alpha$ -(1,1,2,2,2-pentafluoroethyl)- $11\beta$ -[4-(3-pyridinyl)phenyl]estr-4,15-dien-3-one;

30  $11\beta$ -(4-acetylphenyl)- $17\beta$ -hydroxy- $17\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one;

4'-[ $17\beta$ -hydroxy-3-oxo- $17\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-11 $\beta$ -yl][1,1'-biphenyl]-4-carbonitrile;

$11\beta$ -(4'-fluoro[1,1'-biphenyl]-4-yl)- $17\beta$ -hydroxy- $17\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one;

17 $\beta$ -hydroxy-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)-11 $\beta$ -[4-(3-pyridinyl)phenyl]estra-4,9-dien-3-one;

11 $\beta$ -(4-acetylphenyl)-17 $\beta$ -hydroxy-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4,9,15-trien-3-one;

5 4'-[17 $\beta$ -hydroxy-3-oxo-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4,9,15-trien-11 $\beta$ -yl][1,1'-biphenyl]-4-carbonitrile;

11 $\beta$ -(4'-fluoro[1,1'-biphenyl]-4-yl)-17 $\beta$ -hydroxy-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4,9,15-trien-3-one;

17 $\beta$ -hydroxy-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)-11 $\beta$ -[4-(3-pyridinyl)phenyl]estra-4,9,15-trien-3-one;

10 6'-acetyl-9,11 $\alpha$ -dihydro-17 $\beta$ -hydroxy-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)-4'H-naphth[3',2',1':10,9,11]estr-4-en-3-one;

4-[9,11 $\alpha$ -dihydro-17 $\beta$ -hydroxy-3-oxo-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)-4'H-naphth[3',2',1':10,9,11]estr-4-en-6'-yl]benzonitrile;

15 9,11 $\alpha$ -dihydro-6'-(4-fluorophenyl)-17 $\beta$ -hydroxy-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)-4'H-naphth[3',2',1':10,9,11]estr-4-en-3-one;

9,11 $\alpha$ -dihydro-17 $\beta$ -hydroxy-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)-6'-(3-pyridinyl)-4'H-naphth[3',2',1':10,9,11]estr-4-en-3-one;

6'-acetyl-9,11 $\alpha$ -dihydro-17 $\beta$ -hydroxy-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)-4'H-naphth[3',2',1':10,9,11]estra-4,15-dien-3-one;

20 4-[9,11 $\alpha$ -dihydro-17 $\beta$ -hydroxy-3-oxo-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)-4'H-naphth[3',2',1':10,9,11]estra-4,15-dien-6'-yl]benzonitrile;

9,11 $\alpha$ -dihydro-6'-(4-fluorophenyl)-17 $\beta$ -hydroxy-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)-4'H-naphth[3',2',1':10,9,11]estra-4,15-dien-3-one;

25 9,11 $\alpha$ -dihydro-17 $\beta$ -hydroxy-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)-6'-(3-pyridinyl)-4'H-naphth[3',2',1':10,9,11]estra-4,15-dien-3-one;

17 $\beta$ -hydroxy-11 $\beta$ -(4-hydroxyphenyl)-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one;

17 $\beta$ -hydroxy-11 $\beta$ -(4-hydroxyphenyl)-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)estr-4-en-3-one;

30

9,11 $\alpha$ -dihydro-6',17 $\beta$ -dihydroxy-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)-4'H-naphth[3',2',1':10,9,11]estr-4-en-3-one;

11 $\beta$ -[4-(acetyloxy)phenyl]-17 $\beta$ -hydroxy-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one;

5 11 $\beta$ -[4-(acetyloxy)phenyl]-17 $\beta$ -hydroxy-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4-en-3-one

6'-acetyloxy-9,11 $\alpha$ -dihydro-17 $\beta$ -hydroxy-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)-4'H-naphth[3',2',1':10,9,11]estr-4-en-3-one;

10 17 $\beta$ -hydroxy-11 $\beta$ -[4-(hydroxymethyl)phenyl]-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one;

17 $\beta$ -hydroxy-11 $\beta$ -[4-(hydroxymethyl)phenyl]-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4-en-3-one;

9,11 $\alpha$ -dihydro-17 $\beta$ -hydroxy-6'-hydroxymethyl-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)-4'H-naphth[3',2',1':10,9,11]estr-4-en-3-one;

15 4-[17 $\beta$ -hydroxy-3-oxo-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-11 $\beta$ -yl]benzaldehyde;

4-[17 $\beta$ -hydroxy-3-oxo-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4-en-11 $\beta$ -yl]benzaldehyde;

9,11 $\alpha$ -dihydro-17 $\beta$ -hydroxy-3-oxo-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)-4'H-naphth[3',2',1':10,9,11]estr-4-en-6'-al;

20 4-[17 $\beta$ -hydroxy-3-oxo-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-11 $\beta$ -yl]benzoic acid methyl ester;

4-[17 $\beta$ -hydroxy-3-oxo-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4-en-11 $\beta$ -yl]benzoic acid methyl ester;

25 9,11 $\alpha$ -dihydro-17 $\beta$ -hydroxy-3-oxo-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)-4'H-naphth[3',2',1':10,9,11]estr-4-en-6'-carboxylic acid methyl ester;

17 $\beta$ -hydroxy-11 $\beta$ -[4-(1-hydroxyethyl)phenyl]-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one;

30 17 $\beta$ -hydroxy-11 $\beta$ -[4-(1-hydroxyethyl)phenyl]-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4-en-3-one;

9,11 $\alpha$ -dihydro-17 $\beta$ -hydroxy-6'-(1-hydroxyethyl)-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)-4'H-naphth[3',2',1':10,9,11]estr-4-en-3-one.

Preferred is 11 $\beta$ -(4-acetylphenyl)-17 $\beta$ -hydroxy-17 $\alpha$ -(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one (≡ Compound A).

5 The antigestagens can, for example, be applied locally, topically, enterally or parenterally.

For the preferred oral administration, particularly suitable are tablets, dragees, capsules, pills, suspensions or solutions which can be prepared in a conventional manner with additives and carriers used in pharmacy. For local or topical application, 10 vaginal pessaries or percutaneous systems such as skin plasters can be used for example. For parenteral application, particularly suitable are solutions, preferably oily or aqueous solutions, as well as suspensions or emulsions. Ampules are convenient unit dosages.

15 According to a preferred mode of operation, the 17 $\alpha$ - fluoralkylated progesterone receptor antagonist is typically administered over a period of 1 to 6 days, preferably 1 to 4 days, and more preferably on day(s) 1-3 after ovulation and/or the removal of oocytes. Typically, the antigestagen is administered over a period of 1 to 6 days, preferably 1-4 days, and more preferably 1-3 days after ovulation induction with e.g. a chorionic gonadotropin.

20 Surprisingly, according the invention, it has been found that low doses of a 17 $\alpha$ -fluoralkylated progesterone receptor antagonists are effective in the methods disclosed herein. The 17 $\alpha$ -fluoralkylated progesterone receptor antagonists are preferably administered to a human female subject in a daily dosage amount of up to 10 mg per subject, preferably 0.1 - 2 mg per subject, more preferably 0.1-1 mg per subject, and most preferably 0.1-0.7 mg per subject. For mammals in general, a daily dosage amount is typically 0.01-1 mg/kg, preferably 0.01-0.3 mg/kg, and more preferably 0.01-0.1 mg/kg. The daily dose of antigestagen can be administered as a single dose or as divided dosages throughout the day.

25 In a preferred embodiment according to the invention, the antigestagen is administered on a single day to a human subject in an amount of 0.1 - 2 mg/per subject, more preferably 0.1-1 mg/per subject, and most preferably 0.1-0.7 mg/per

subject or to a mammal in an amount of 0.01-1 mg/kg, preferably 0.01-0.3 mg/kg, and more preferably 0.01-0.1 mg/kg. For example, on day 1, 2, 3, 4, 5 or 6 following ovulation, removal of oocytes, or administration of a chorionic gonadotropin, preferably day 1-3, and more preferably day 2.

5 For any particular 17 $\alpha$ -fluoralkylated progesterone receptor antagonist, the most appropriate dose can be determined, for example, by evaluation of the potency to induce premature menstruation in advanced luteal phase of the human cycle as described in e.g. Herrmann, W., et al, 1982, *Comptes Rendus* 294:933. The use of antigestagens for delaying endometrial maturation has been previously described, 10 for example, in U.S. Patent No. 4,764,513, EP 0219447B1, Hegele-Hartung et al., 1992, *Endocrinology* 131:2446-2460, all of which are incorporated herein by reference in their entirety.

15 The compounds of this invention can be employed in admixture with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for, for example, parenteral, enteral (e.g., oral) or topical application which do not deleteriously react with the active compounds. Suitable pharmaceutically acceptable carriers include but are not limited to water, salt 20 solutions, alcohols, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelatine, carbohydrates such as lactose, amylase or starch, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose, polyvinyl pyrrolidone, etc. The pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances 25 and the like which do not deleteriously react with the active compounds. They can also be combined, where desired, with other active agents, e.g., vitamins.

30 Sustained or directed release compositions can be formulated, e.g., liposomes or those wherein the active compound is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc. It is also possible to freeze-dry the new compounds and use the lyophilizates obtained, for example, for the preparation of products for injection.

For topical application, there are employed as nonsprayable forms, viscous to semi-solid or solid forms comprising a carrier compatible with topical application and having a dynamic viscosity preferably greater than water. Suitable formulations include but are not limited to solutions, suspensions, emulsions, creams, ointments, 5 powders, liniments, salves, aerosols, etc., which are, if desired, sterilized or mixed with auxiliary agents, e.g., preservatives, stabilizers, wetting agents, buffers or salts for influencing osmotic pressure, etc. For topical application, also suitable are sprayable aerosol preparations wherein the active ingredient, preferably in combination with a solid or liquid inert carrier material, is packaged in a squeeze 10 bottle or in admixture with a pressurized volatile, normally gaseous propellant, e.g., a freon.

It will be appreciated that the actual preferred amounts of active compound in a specific case will vary according to the specific compound being utilized, the 15 particular compositions formulated, the mode of application, and the particular situs and organism being treated. Dosages for a given host can be determined using conventional considerations, e.g., by customary comparison of the differential activities of the subject compounds of a known agent, e.g., by means of an appropriate, conventional pharmacological protocol.

#### **BRIEF DESCRIPTION OF THE FIGURES**

Figure 1 is a schematic illustration of the experiment described in Example 1. The day of administration of human chorionic gonadotropin (hCG) was designated as day 0 of pseudopregnancy (d0). As shown in the diagram, ovarian stimulation of the animals occurred on -d3, -d2 and -d1 of pseudopregnancy induction and the 25 progesterone receptor antagonist was administered on d2 of psuedopregnancy.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely 30 illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

In the foregoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius; and, unless otherwise indicated, all parts and percentages are by weight.

5 The entire disclosure of all applications, patents and publications, cited above or below, are hereby incorporated by reference.

### **EXAMPLES**

Example 1: Improvement of endometrial receptivity with low doses of a 17 $\alpha$ -fluoralkylated progesterone receptor antagonist in the superovulated rabbit model.

10 The effects of a 17 $\alpha$ -fluoralkylated progesterone receptor antagonist on endometrial activity was evaluated in the superovulated pseudopregnant rabbit model. The pseudopregnancy of the rabbit has proven to be a model system for the human luteal phase (Beier and Kuhnel, 1973, *Hormone Res.* 4:1-27; Fischer et al., 1985, *Fertililitat* 1:101-109. In this species, ovarian stimulation induces an advancement of secretory transformation (Delbos-Winter et al., 1987, *Fertililitat* 3: 87-93) as well as an enhancement of gland formation.

15 A total of 25 sexually mature nulliparous New Zealand White rabbits with a body weight of 3.1 to 4.0 kg were used for the analysis. The animals were divided into two control groups (groups 1 and 2) and three treatment groups (groups 3-5), with five animals in each group.

20 Control group 1 received 75 international units (IU) of human chorionic gonadotropin (hCG) administered intravenously in order to induce pseudopregnancy. The day of hCG-injection was designated as day 0 of pseudopregnancy (d0 p.hCG).

25 Control group 2 and treatment groups 3, 4, and 5 were gonadotropin-stimulated with 5 IU of the human menopausal gonadotropin (HMG) Pergonal® (Serono Pharma, Unterschleißheim, Germany) for 3 days, by subcutaneous injection, in order to induce multiple follicular growth. Pseudopregnancy was induced by the administration of human chorionic gonadotropin (hCG) as described for control group 1 above.

Treatment groups 3, 4 and 5 also received a single per oral application of a  $17\alpha$  -fluoralkylated progesterone receptor antagonist (Compound A) two days after pseudopregnancy induction with the administration of human chorionic gonadotropin (d2 p.hCG). The detailed treatment schedule is shown in Figure 1.

5                    Animals in all treatment groups were sacrificed on day 5 following pseudopregnancy induction (d5 p.hCG), and uteri were removed. Relative uterine wet weights were determined (in mg/100 g body weight) and a part of the uterus was snap frozen in liquid nitrogen for determination of uteroglobin expression by in situ hybridization. Uteroglobin expression is known as a highly sensitive parameter  
10                    for determination of endometrial receptivity (Beier, H.M., 1968, *Biochem Biophys. Acta* 160:289-291; Beier, H.M., 1982, in: Beier, H.M. and Karlson, P. (eds.), Proteins and Steroids in Early Pregnancy), and is a marker for secretory activity (Beier, 1976, *J. Reprod. Fertil. Suppl.* 25:53-69) and differentiation of the endometrial epithelium (Krusche & Beier, 1994, *Ann. Anat.* 176:23-31). In situ hybridization for detection of uteroglobin expression was conducted as previously described in Krusche & Beier, above. Another piece of the uterus was removed and processed for paraffin histology in order to determine the endometrial transformation status using the McPhail-Index (McPhail Mk, 1934, *J. Phys.* 83:145-156) The McPhail Index reflects different degrees of progestogenic (transforming) activity in the rabbit endometrium:

15                    20

1.            no transformation
2.            low transformation
3.            pronounced transformation
4.            high transformation

25                    The results are presented in Table 1 below.

Table 1

Effect of a single treatment of a  $17\alpha$ -fluoralkylated progesterone receptor antagonist on uterus weight, endometrial transformation, and uteroglobin mRNA expression at five days after pseudopregnancy induction (d5 p.hCG) in the  
30                    superovulated pseudopregnant rabbit.

Group	Treatment Schedule			Measurement endpoints at d5 p. hCG		
	-d3, -d2, -d1 p.hCG	d0 p.hCG	d2 p.hCG	Uterine wet weight [mg/kg] [x ± SD]	Mc-Phail	Uteroglobin ISH [expression in luminal epithelial cells]
	5 IU HMG	75 IU HCG	Progesterone receptor antagonist [mg/kg]			
1	-	+	-	324 ± 99	3.2 ± 0.2	very high expression
2	+	+	0	448 ± 80	3.9 ± 0.1	very low expression
3	+	+	0.1	305 ± 48	3.0 ± 0.1	very high expression
4	+	+	1	227 ± 56	1.5 ± 0.3	very low expression
5	+	+	10	144 ± 30	1.1 ± 0.3	absent

As shown in the table, animals which were subject to ovarian hyperstimulation, but which were not treated with an antigestagen (Group 2), showed advanced endometrial maturation as demonstrated by nearly indetectable uteroglobin expression in

10 endometrial luminal epithelial cells, the weight of the uterus, and the relatively high Mc-Phail index score. However, animals which were subject to ovarian hyperstimulation and which were treated with an antigestagen, Groups 3-5, showed a delay in endometrial maturation, as demonstrated by the uterine wet weights and the Mc-Phail index scores. For animals which were treated with a low dose of 15 progesterone receptor antagonist, 0.1 mg/kg (Group 3), endometrial maturation roughly corresponded with that of control animals which were not subject to ovarian hyperstimulation (Group 1). In contrast, higher doses of progesterone receptor antagonist, 1 mg/kg (group 4) and 10 mg/kg (group 5), apparently counteracted the advancement of endometrium maturation associated with ovarian 20 hyperstimulation and also delayed the timing of maturation beyond that observed in animals which were not subject to hyperovarian stimulation (Group 1).

The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.